GLP1R and type 2 diabetes mellitus: While the extremely short half-life prevents the therapeutic use of GLP-17–36, incretin-based therapies have established a foothold in T2D management through the introduction of oral DPP-IV inhibitors and injectable long-acting GLP-1 receptor agonists 9.